CASI Pharmaceuticals Inc (NASDAQ:CASI) CEO Buys $5,609,609.40 in Stock

CASI Pharmaceuticals Inc (NASDAQ:CASI) CEO Wei-Wu He purchased 2,952,426 shares of the business’s stock in a transaction on Wednesday, July 22nd. The shares were purchased at an average price of $1.90 per share, with a total value of $5,609,609.40. Following the completion of the purchase, the chief executive officer now owns 4,836,523 shares in the company, valued at $9,189,393.70. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Wei-Wu He also recently made the following trade(s):

  • On Wednesday, May 20th, Wei-Wu He purchased 86,265 shares of CASI Pharmaceuticals stock. The shares were purchased at an average price of $2.61 per share, with a total value of $225,151.65.
  • On Monday, May 18th, Wei-Wu He purchased 438,932 shares of CASI Pharmaceuticals stock. The shares were purchased at an average price of $2.05 per share, with a total value of $899,810.60.

Shares of NASDAQ:CASI opened at $1.94 on Monday. The stock has a 50 day moving average of $2.42 and a 200 day moving average of $2.28. The company has a market cap of $195.78 million, a PE ratio of -4.04 and a beta of 1.02. CASI Pharmaceuticals Inc has a 12-month low of $1.15 and a 12-month high of $3.82.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.02. The company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $0.79 million. On average, research analysts predict that CASI Pharmaceuticals Inc will post -0.3 EPS for the current year.

Several large investors have recently made changes to their positions in CASI. Wellesley Investment Partners LLC bought a new position in shares of CASI Pharmaceuticals during the 1st quarter valued at approximately $30,000. BNP Paribas Arbitrage SA boosted its stake in CASI Pharmaceuticals by 111.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 15,473 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 8,142 shares during the period. SG Americas Securities LLC bought a new position in CASI Pharmaceuticals in the 1st quarter worth approximately $37,000. Heritage Investors Management Corp boosted its stake in CASI Pharmaceuticals by 84.0% in the 1st quarter. Heritage Investors Management Corp now owns 18,579 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 8,484 shares during the period. Finally, Marshall Wace LLP bought a new position in CASI Pharmaceuticals in the 1st quarter worth approximately $44,000. Institutional investors own 21.54% of the company’s stock.

Separately, BidaskClub upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 27th.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Recommended Story: Day Trading

Insider Buying and Selling by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.